Amgen scores FDA approval for Stelara biosimilar
The Amgen biosimilar Wezlana has been approved for all indications and is forecasted to yield $455m in 2029.
02 November 2023
02 November 2023
The Amgen biosimilar Wezlana has been approved for all indications and is forecasted to yield $455m in 2029.
The company generated a £22.2bn turnover during the first nine months of the year.
As per WHO, about one in ten medical products in low-income and middle-income countries is substandard or falsified.
Litfulo is an enzyme inhibitor therapy in the form of an oral capsule that lowers inflammation and leads to hair regrowth.
Cellectis will receive a $25m upfront payment and up to $220m in equity investment, along with potential milestone based and royalty payments.
Aldeyra will be eligible to receive up to $300m in commercial and regulatory milestone payments.
ONL Therapeutics plans to raise $75-$100m to support Phase II trials in geographic atrophy and open-angle glaucoma.
Jonathan Milner suspended his vote against campaign today in the wake of "extensive feedback" from Abcam shareholders.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Despite challenging business conditions in 2021 and 2022, large CMOs were still involved in acquisitions to enhance their capabilities or scale of production. Catalent and Recipharm were particularly active in acquiring companies during this period, and these acquisitions had a focus on advanced biologic capabilities related to cell and gene therapies. CMOs are increasingly targeting companies with sophisticated (biologic and specialized) capabilities to manufacture modern drugs and seek high-value contracts.
Give your business an edge with our leading industry insights.